Literature DB >> 24744599

Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma.

Xiao-Qing Yang1, Yun-Fei Xu1, Sen Guo1, Yi Liu1, Shang-Lei Ning1, Xiao-Fei Lu1, Hui Yang1, Yu-Xin Chen1.   

Abstract

AIM: To investigate the correlation between nerve growth factor-tropomyosin-receptor-kinase (NGF-TrkA) signaling pathway and prognosis in intrahepatic cholangiocarcinoma (IHCC).
METHODS: NGF and TrkA expression in 83 samples of IHCC was assessed by immunohistochemistry. Correlations between NGF-TrkA expression and clinicopathological features were analyzed by χ² test. Moreover, we evaluated the association between NGF-TrkA and overall survival by univariate and multivariate analysis. With experiments in vitro, we investigated the crucial role of NGF-TrkA on proliferation and invasion of IHCC cells with recombinant NGF-β stimulation.
RESULTS: We found that NGF and TrkA expression was significantly related with differentiation (P = 0.024) and intraneural invasion (P = 0.003), respectively. Additionally, double higher expression of NGF and TrkA was identified as an independent prognostic factor in IHCC (P = 0.003). Moreover, we demonstrated that NGF-TrkA signaling pathway can promote IHCC proliferation and invasion.
CONCLUSION: NGF-TrkA double higher expression is an independent prognostic factor in IHCC. NGF-TrkA pathway can promote IHCC progression, indicating that NGF-TrkA may become a potential drug target.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma; Nerve growth factor; Prognosis; Progression; Tropomyosin-receptor-kinase

Mesh:

Substances:

Year:  2014        PMID: 24744599      PMCID: PMC3983466          DOI: 10.3748/wjg.v20.i14.4076

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways.

Authors:  S Descamps; R A Toillon; E Adriaenssens; V Pawlowski; S M Cool; V Nurcombe; X Le Bourhis; B Boilly; J P Peyrat; H Hondermarck
Journal:  J Biol Chem       Date:  2001-02-28       Impact factor: 5.157

2.  The severity of neural invasion is associated with shortened survival in colon cancer.

Authors:  Florian Liebl; Ihsan Ekin Demir; Robert Rosenberg; Alexandra Boldis; Esra Yildiz; Kristina Kujundzic; Timo Kehl; Dominic Dischl; Tibor Schuster; Matthias Maak; Karen Becker; Rupert Langer; Melanie Laschinger; Helmut Friess; Güralp O Ceyhan
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

3.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Authors:  Daniela Sia; Yujin Hoshida; Augusto Villanueva; Sasan Roayaie; Joana Ferrer; Barbara Tabak; Judit Peix; Manel Sole; Victoria Tovar; Clara Alsinet; Helena Cornella; Brandy Klotzle; Jian-Bing Fan; Christian Cotsoglou; Swan N Thung; Josep Fuster; Samuel Waxman; Juan Carlos Garcia-Valdecasas; Jordi Bruix; Myron E Schwartz; Rameen Beroukhim; Vincenzo Mazzaferro; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-04       Impact factor: 22.682

4.  Nerve growth factor-beta expression is associated with lymph node metastasis and nerve infiltration in human hilar cholangiocarcinoma.

Authors:  Lei-Bo Xu; Chao Liu; Guo-Quan Gao; Xian-Huan Yu; Rui Zhang; Jie Wang
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

Review 5.  Neurotrophin signaling through the p75 neurotrophin receptor.

Authors:  Philippe P Roux; Philip A Barker
Journal:  Prog Neurobiol       Date:  2002-06       Impact factor: 11.685

Review 6.  Trk kinase inhibitors as new treatments for cancer and pain.

Authors:  Tao Wang; Dingwei Yu; Michelle L Lamb
Journal:  Expert Opin Ther Pat       Date:  2009-03       Impact factor: 6.674

7.  Dependence receptor UNC5D mediates nerve growth factor depletion-induced neuroblastoma regression.

Authors:  Yuyan Zhu; Yuanyuan Li; Seiki Haraguchi; Meng Yu; Miki Ohira; Toshinori Ozaki; Atsuko Nakagawa; Toshikazu Ushijima; Eriko Isogai; Haruhiko Koseki; Yohko Nakamura; Cuize Kong; Patrick Mehlen; Hirofumi Arakawa; Akira Nakagawara
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

8.  TrkA overexpression enhances growth and metastasis of breast cancer cells.

Authors:  C Lagadec; S Meignan; E Adriaenssens; B Foveau; E Vanhecke; R Romon; R-A Toillon; B Oxombre; H Hondermarck; X Le Bourhis
Journal:  Oncogene       Date:  2009-03-30       Impact factor: 9.867

9.  Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.

Authors:  Ben Davidson; Reuven Reich; Philip Lazarovici; Jahn M Nesland; Martina Skrede; Björn Risberg; Claes G Tropé; Vivi Ann Flørenes
Journal:  Clin Cancer Res       Date:  2003-06       Impact factor: 12.531

Review 10.  Trk receptor expression and inhibition in neuroblastomas.

Authors:  Garrett M Brodeur; Jane E Minturn; Ruth Ho; Anisha M Simpson; Radhika Iyer; Carly R Varela; Jennifer E Light; Venkatadri Kolla; Audrey E Evans
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

View more
  14 in total

1.  TRAF6 expression is associated with poorer prognosis and high recurrence in urothelial bladder cancer.

Authors:  Hanli Wu; Aixia Hao; Honghong Cui; Wenbin Wu; Huanrong Yang; Baohong Hu; Peng Li
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

2.  Holliday junction-recognizing protein promotes cell proliferation and correlates with unfavorable clinical outcome of hepatocellular carcinoma.

Authors:  Baohong Hu; Qianli Wang; Yueju Wang; Jian Chen; Peng Li; Mingyong Han
Journal:  Onco Targets Ther       Date:  2017-05-17       Impact factor: 4.147

3.  Cul4B promotes the progression of ovarian cancer by upregulating the expression of CDK2 and CyclinD1.

Authors:  Peng-Jing Duan; Juan-Hong Zhao; Li-Li Xie
Journal:  J Ovarian Res       Date:  2020-07-04       Impact factor: 4.234

4.  High miR-718 Suppresses Phosphatase and Tensin Homolog (PTEN) Expression and Correlates to Unfavorable Prognosis in Gastric Cancer.

Authors:  Shufang Liu; Ying Tian; Chanchan Zhu; Xiaoqing Yang; Qing Sun
Journal:  Med Sci Monit       Date:  2018-08-22

5.  CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma.

Authors:  Shimiao Li; Yi Chai; Yanbao Ding; Tinghao Yuan; Changwen Wu; Changwen Huang
Journal:  Oncol Rep       Date:  2019-05-28       Impact factor: 3.906

6.  NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.

Authors:  Kang-Shuai Li; Xiao-Dong Zhu; Hong-Da Liu; Shi-Zhe Zhang; Xiao-Long Li; Nan Xiao; Xue-Feng Liu; Bin Xu; Ming Lei; Yuan-Yuan Zhang; Wen-Kai Shi; Man-Qing Cao; Yun-Fei Xu; Zhao-You Tang; Hui-Chuan Sun
Journal:  Cell Death Dis       Date:  2020-05-07       Impact factor: 8.469

7.  Increased Expression of Holliday Junction-Recognizing Protein (HJURP) as an Independent Prognostic Biomarker in Advanced-Stage Serous Ovarian Carcinoma.

Authors:  Lin Li; Xiaoli Li; Qin Meng; Abdul Qadir Khan; Xiaomei Chen
Journal:  Med Sci Monit       Date:  2018-05-10

8.  An Immunohistochemical Study of Stathmin 1 Expression in Osteosarcoma Shows an Association with Metastases and Poor Patient Prognosis.

Authors:  Changlei Zhao; Hailing Li; Lingling Wang; Wei Sun
Journal:  Med Sci Monit       Date:  2018-08-31

9.  Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.

Authors:  Rongqi Sun; Zengli Liu; Bo Qiu; Tianli Chen; Zhipeng Li; Xiaoming Zhang; Yunfei Xu; Zongli Zhang
Journal:  EBioMedicine       Date:  2019-09-03       Impact factor: 8.143

Review 10.  Neuroendocrine Changes in Cholangiocarcinoma Growth.

Authors:  Keisaku Sato; Heather Francis; Tianhao Zhou; Fanyin Meng; Lindsey Kennedy; Burcin Ekser; Leonardo Baiocchi; Paolo Onori; Romina Mancinelli; Eugenio Gaudio; Antonio Franchitto; Shannon Glaser; Gianfranco Alpini
Journal:  Cells       Date:  2020-02-13       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.